Review



mdck cell culture–derived influenza vaccine (cciv)  (Novartis)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Novartis mdck cell culture–derived influenza vaccine (cciv)
    Mdck Cell Culture–Derived Influenza Vaccine (Cciv), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cciv/trivalent+mdck+cell+culture+derived+influenza+vaccine+optaflu/pm29642288-148-11-15
    Average 90 stars, based on 1 article reviews
    mdck cell culture–derived influenza vaccine (cciv) - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Vaccines:

    Article Title: Vaccines for preventing influenza in healthy adults
    Article Snippet: Both CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 μg of haemagglutinin per 0.5 mL dose of each of the following virus strains: A/Solomon Islands/3/2006 (H1N1)–like A/Wisconsin/67/2005 (H3N2)–like B/Malaysia/2506/2004–like Preparations were administered in the deltoid muscle of the non‐dominant arm. .. Both CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 μg of haemagglutinin per 0.5 mL dose of each of the following virus strains: A/Solomon Islands/3/2006 (H1N1)–like A/Wisconsin/67/2005 (H3N2)–like B/Malaysia/2506/2004–like Preparations were administered in the deltoid muscle of the non‐dominant arm. ..

    Article Title: Vaccines for preventing influenza in healthy adults
    Article Snippet: .. Both CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 μg of haemagglutinin per 0.5 mL dose of each of the following virus strains: A/Solomon Islands/3/2006 (H1N1)-like A/Wisconsin/67/2005 (H3N2)-like B/Malaysia/2506/2004-like Preparations were administered in the deltoid muscle of the non-dominant arm. ..

    Article Title: Vaccines for preventing influenza in healthy adults
    Article Snippet: Participants , Participants were recruited at 56 centres in the USA, Finland, and Poland. Major exclusion criteria: health condition for which inactivated vaccine is recommended, employment prone to influenza transmission, influenza vaccination or laboratory‐confirmed influenza within 6 months of enrolment, history of Guillain‐Barré syndrome, a temperature of 37.8 °C and/or acute illness within 3 days of enrolment, and pregnancy or breastfeeding. A total of 11,404 participants were randomised: 11,382 were vaccinated and 10,844 (95%) completed the study. , . .. Interventions , Individuals aged 18 to 49 years were randomised equally, with use of an interactive voice response system, to receive a single dose of CCIV, TIV, or placebo. Both CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 μg of haemagglutinin per 0.5 mL dose of each of the following virus strains: A/Solomon Islands/3/2006 (H1N1)–like A/Wisconsin/67/2005 (H3N2)–like B/Malaysia/2506/2004–like Preparations were administered in the deltoid muscle of the non‐dominant arm. Only the vaccine administrator had access to the randomisation code. , . .. Outcomes , Safety Study participants were monitored for 30 minutes after vaccination for immediate reactions. Participants recorded the occurrence, duration, and severity of local injection site and systemic reactions for 7 days after vaccination. Solicited reactions were graded as follows: mild, no limitation of normal daily activities; moderate, some limitation; or severe, unable to perform normal daily activities. Unsolicited reactions were recorded for 21 days after vaccination. Serious adverse events were monitored for the entire study (9 months). Effectiveness Influenza surveillance began 21 days after vaccination. Participants had to report to investigators the occurrence of influenza‐like illness symptoms (fever 37.8 °C plus sore throat or cough, as well as body aches, chills, headache, and runny or stuffy nose). An active survey was also performed by means of weekly phone calls. Participants reporting influenza‐like illness symptoms underwent clinical evaluations; nasal and throat specimens were obtained for laboratory confirmation of influenza virus. Specimens were targeted for collection within 24 hours after symptom onset, with a window of 120 hours. Specimens were cultured on RhMK and tested by PCR. Each study participant was observed during the 6‐month study surveillance period or for 6 months after vaccination, whichever was longer. Study duration was around 9 months. Immunogenicity It was assessed on the first 1045 participants enrolled at USA sites and randomised 8:25:2 to receive CCIV, TIV, or placebo. Serum samples were collected at baseline and 3 weeks after immunisation for seroprotection, seroconversion, and GMT determination. , .

    Article Title: Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.
    Article Snippet: .. CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 mg of hemagglutinin per 0.5-mL dose of each virus strain recommended for the 2007–2008 Northern Hemisphere influenza season: A/Solomon Islands/3/2006 (H1N1)– like, A/Wisconsin/67/2005 (H3N2)–like, and B/Malaysia/2506/ 2004–like. ..

    Article Title: A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
    Article Snippet: Conventional influenza vaccine production methods have limitations due to their reliance on chicken eggs.. We evaluated whether a mammalian cell-culture system could reliably produce an influenza vaccine with favourable tolerability and immunogenicity profiles.. Adult subjects (n = 1200; 18–60 years of age) were randomized (2:2:2:1) to receive either one of three lots of a cell-culture-derived influenza vaccine (CCIV) or an egg-based trivalent inactivated influenza vaccine (TIV).

    Article Title: Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.
    Article Snippet: In 2007, by guest on February 25, 2015 http://cid.oxfordjournals.org/ D ow nloaded from 998 • CID 2010:51 (1 November) • Frey et al the European Medicines Agency approved an MDCK cell culture–derived influenza vaccine (CCIV) (Optaflu; Novartis Vaccines) [10, 11]. .. Approximately 4000 doses of this CCIV have been administered to healthy adult and elderly individuals in 5 trials that evaluated the safety and immunogenicity, compared with Novartis Vaccines’ European (Agrippal) or American (Fluvirin) licensed trivalent inactivated vaccines (TIVs) [11–15]. ..

    Virus:

    Article Title: Vaccines for preventing influenza in healthy adults
    Article Snippet: Both CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 μg of haemagglutinin per 0.5 mL dose of each of the following virus strains: A/Solomon Islands/3/2006 (H1N1)–like A/Wisconsin/67/2005 (H3N2)–like B/Malaysia/2506/2004–like Preparations were administered in the deltoid muscle of the non‐dominant arm. .. Both CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 μg of haemagglutinin per 0.5 mL dose of each of the following virus strains: A/Solomon Islands/3/2006 (H1N1)–like A/Wisconsin/67/2005 (H3N2)–like B/Malaysia/2506/2004–like Preparations were administered in the deltoid muscle of the non‐dominant arm. ..

    Article Title: Vaccines for preventing influenza in healthy adults
    Article Snippet: .. Both CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 μg of haemagglutinin per 0.5 mL dose of each of the following virus strains: A/Solomon Islands/3/2006 (H1N1)-like A/Wisconsin/67/2005 (H3N2)-like B/Malaysia/2506/2004-like Preparations were administered in the deltoid muscle of the non-dominant arm. ..

    Article Title: Vaccines for preventing influenza in healthy adults
    Article Snippet: Participants , Participants were recruited at 56 centres in the USA, Finland, and Poland. Major exclusion criteria: health condition for which inactivated vaccine is recommended, employment prone to influenza transmission, influenza vaccination or laboratory‐confirmed influenza within 6 months of enrolment, history of Guillain‐Barré syndrome, a temperature of 37.8 °C and/or acute illness within 3 days of enrolment, and pregnancy or breastfeeding. A total of 11,404 participants were randomised: 11,382 were vaccinated and 10,844 (95%) completed the study. , . .. Interventions , Individuals aged 18 to 49 years were randomised equally, with use of an interactive voice response system, to receive a single dose of CCIV, TIV, or placebo. Both CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 μg of haemagglutinin per 0.5 mL dose of each of the following virus strains: A/Solomon Islands/3/2006 (H1N1)–like A/Wisconsin/67/2005 (H3N2)–like B/Malaysia/2506/2004–like Preparations were administered in the deltoid muscle of the non‐dominant arm. Only the vaccine administrator had access to the randomisation code. , . .. Outcomes , Safety Study participants were monitored for 30 minutes after vaccination for immediate reactions. Participants recorded the occurrence, duration, and severity of local injection site and systemic reactions for 7 days after vaccination. Solicited reactions were graded as follows: mild, no limitation of normal daily activities; moderate, some limitation; or severe, unable to perform normal daily activities. Unsolicited reactions were recorded for 21 days after vaccination. Serious adverse events were monitored for the entire study (9 months). Effectiveness Influenza surveillance began 21 days after vaccination. Participants had to report to investigators the occurrence of influenza‐like illness symptoms (fever 37.8 °C plus sore throat or cough, as well as body aches, chills, headache, and runny or stuffy nose). An active survey was also performed by means of weekly phone calls. Participants reporting influenza‐like illness symptoms underwent clinical evaluations; nasal and throat specimens were obtained for laboratory confirmation of influenza virus. Specimens were targeted for collection within 24 hours after symptom onset, with a window of 120 hours. Specimens were cultured on RhMK and tested by PCR. Each study participant was observed during the 6‐month study surveillance period or for 6 months after vaccination, whichever was longer. Study duration was around 9 months. Immunogenicity It was assessed on the first 1045 participants enrolled at USA sites and randomised 8:25:2 to receive CCIV, TIV, or placebo. Serum samples were collected at baseline and 3 weeks after immunisation for seroprotection, seroconversion, and GMT determination. , .

    Article Title: Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.
    Article Snippet: .. CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 mg of hemagglutinin per 0.5-mL dose of each virus strain recommended for the 2007–2008 Northern Hemisphere influenza season: A/Solomon Islands/3/2006 (H1N1)– like, A/Wisconsin/67/2005 (H3N2)–like, and B/Malaysia/2506/ 2004–like. ..

    Northern Blot:

    Article Title: Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.
    Article Snippet: .. CCIV and TIV (Novartis Vaccines and Diagnostics) contained 15 mg of hemagglutinin per 0.5-mL dose of each virus strain recommended for the 2007–2008 Northern Hemisphere influenza season: A/Solomon Islands/3/2006 (H1N1)– like, A/Wisconsin/67/2005 (H3N2)–like, and B/Malaysia/2506/ 2004–like. ..

    Immunopeptidomics:

    Article Title: Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.
    Article Snippet: In 2007, by guest on February 25, 2015 http://cid.oxfordjournals.org/ D ow nloaded from 998 • CID 2010:51 (1 November) • Frey et al the European Medicines Agency approved an MDCK cell culture–derived influenza vaccine (CCIV) (Optaflu; Novartis Vaccines) [10, 11]. .. Approximately 4000 doses of this CCIV have been administered to healthy adult and elderly individuals in 5 trials that evaluated the safety and immunogenicity, compared with Novartis Vaccines’ European (Agrippal) or American (Fluvirin) licensed trivalent inactivated vaccines (TIVs) [11–15]. ..



    Similar Products

    86
    Wolters Kluwer Health act cciv
    Act Cciv, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cciv/act+cciv/10__24294_slash_jipd9672-49-23-69
    Average 86 stars, based on 1 article reviews
    act cciv - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    90
    Novartis mdck cell culture–derived influenza vaccine (cciv)
    Mdck Cell Culture–Derived Influenza Vaccine (Cciv), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cciv/trivalent+mdck+cell+culture+derived+influenza+vaccine+optaflu/pm29642288-148-11-15
    Average 90 stars, based on 1 article reviews
    mdck cell culture–derived influenza vaccine (cciv) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Novartis cciv
    Cciv, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cciv/cciv/10__1002_slash_14651858__cd001269__pub6-1905-1-4
    Average 90 stars, based on 1 article reviews
    cciv - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Novartis seasonal trivalent subunit cciv
    Seasonal Trivalent Subunit Cciv, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cciv/seasonal+trivalent+subunit+cciv/pm25968069-66-7-1
    Average 90 stars, based on 1 article reviews
    seasonal trivalent subunit cciv - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Novartis cciv optaflu® novartis vaccines
    Cciv Optaflu® Novartis Vaccines, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cciv/cciv+optaflu++novartis+vaccines/pm22418809-129-2-4
    Average 90 stars, based on 1 article reviews
    cciv optaflu® novartis vaccines - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Novartis mdck cell culture-derived influenza vaccine (cciv)
    Mdck Cell Culture Derived Influenza Vaccine (Cciv), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cciv/trivalent+mdck+cell+culture+derived+influenza+vaccine+optaflu/pm20868284-34-32-36
    Average 90 stars, based on 1 article reviews
    mdck cell culture-derived influenza vaccine (cciv) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results